Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ramucirumab with paclitaxel in gastric cancer completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-19